Great launch, single-product price risk
- XDEMVY is Tarsus's only commercial product and generated $146.1 million of Q1 2026 net product sales.
- Management guided to $670 million to $700 million of 2026 net product sales.
- Nearly half of 15,000 target eye care providers prescribed XDEMVY at least weekly in Q1 2026.
- Retreatment rates have moved into the mid-teens, compared with management's steady-state goal of about 20%.
- The main debate is valuation: the launch is strong, but the company still depends on one drug.
A strong launch with a narrow base
Tarsus is one of the cleaner commercial biotech stories right now. XDEMVY is the first and only FDA-approved treatment for Demodex blepharitis, an eyelid disease tied to mites. The company is not trying to prove demand from scratch anymore. In Q1 2026, XDEMVY produced $146.1 million of net product sales.
The bull case is simple. More eye care providers are using the drug more often. Management said nearly half of its 15,000 target providers prescribed XDEMVY at least once a week in Q1 2026. Retreatment rates are also rising into the mid-teens, versus a steady-state goal of about 20%. That supports the 2026 sales guide of $670 million to $700 million and the longer-term goal of more than $2 billion in U.S. peak sales.
The next push is depth, not awareness alone. Tarsus plans to deploy Key Account Leaders in the second half of 2026 to focus on the largest and highest-potential practices. If that team lifts prescribing inside accounts that already know XDEMVY, the path to 2027 profitability looks more believable.
The bear case is also clear. This is still a one-product revenue story, and the stock already prices in a lot of success. A miss against 2026 guidance, weak China royalties, or poor Phase 2 data in 2027 would matter because there is not yet a second commercial product to soften the blow.
One approved drug pays the bills
Tarsus makes money by selling XDEMVY in the United States. XDEMVY treats the root cause of Demodex blepharitis, which gives Tarsus a strong first-mover position in an eye care market that did not have an FDA-approved drug for this condition before.
The company sells directly to U.S. eye care providers and patients through the normal prescription drug system. That means growth depends on doctor adoption, patient access, payer coverage, and repeat use when symptoms return.
Outside the United States, Tarsus uses partners. China is the key near-term example, with GrandPharma tied to the launch after 2026 approval. The open question is how big the royalty stream can become, since U.S. sales still drive almost all visible value today.
Tarsus is still investing heavily. It had an accumulated deficit of $433.6 million as of March 31, 2026, and posted a $7.0 million net loss in Q1 2026. The loss is narrowing, but this is not yet a proven profit machine.
Lotilaner is the platform
XDEMVY
XDEMVY is lotilaner ophthalmic solution 0.25% for Demodex blepharitis. It is the only approved product and all current revenue comes from it.
TP-03 in Meibomian Gland Disease
TP-03 uses the same active ingredient in patients with Demodex blepharitis and Meibomian Gland Disease. Tarsus is sharing data with providers because the current XDEMVY label already covers Demodex blepharitis.
TP-04 for Ocular Rosacea
TP-04 is a gel formulation being tested for ocular rosacea. A Phase 2 trial started in December 2025, with topline results expected in the first half of 2027.
TP-05 for Lyme disease prevention
TP-05 is an oral lotilaner tablet being tested as a possible way to prevent Lyme disease after tick exposure. The Calliope Phase 2 trial has about 700 participants, with topline data expected in the first half of 2027.
XDEMVY outside the United States
International growth is expected through partners rather than a full Tarsus sales buildout. China, through GrandPharma, is the main watch item after 2026 approval.
One segment, one revenue source
For Q1 2026, Tarsus managed the business as one operating segment and all revenue came from U.S. XDEMVY net product sales. The extra zero-revenue line below shows that there was no meaningful product diversification in the reported mix.
What could break the story
XDEMVY growth stalls
High impact · Medium oddsAll current revenue depends on XDEMVY. If weekly prescribing stops rising, retreatment rates flatten below the roughly 20% steady-state goal, or practices do not add more patients, the 2026 guide becomes harder to hit.
Key Account Leaders do not add enough depth
Medium impact · Medium oddsTarsus is adding Key Account Leaders in the second half of 2026 to deepen use in large practices. The plan makes sense, but management has not given a clear revenue contribution target for this team.
Payer or patient access friction
High impact · Medium oddsA prescription drug launch can slow if patients face high out-of-pocket costs or if payers make access harder. Since XDEMVY is the revenue base, even small access issues can show up quickly in sales.
Pipeline data disappoints in 2027
Medium impact · Medium oddsTP-04 and TP-05 are important because they could reduce reliance on one eye drug. Both are still in Phase 2, so they must prove safety and efficacy before they can become real products or attract partners.
Valuation leaves little room for error
High impact · Medium oddsThe business is executing well, but investors are already paying for a large XDEMVY opportunity. If growth merely slows rather than collapses, the stock could still react badly because expectations are high.
In one breath
What does Tarsus Pharmaceuticals make?
Tarsus sells XDEMVY, an FDA-approved eye drop for Demodex blepharitis. The disease is linked to mites on the eyelids, and XDEMVY is designed to treat that root cause.
Why is XDEMVY important to Tarsus stock?
XDEMVY is the whole revenue base today. It generated $146.1 million of Q1 2026 net product sales, and management expects $670 million to $700 million for full-year 2026.
When are the next big Tarsus pipeline readouts?
The key readouts are expected in the first half of 2027. TP-04 has Phase 2 data expected in ocular rosacea, and TP-05 has Phase 2 Calliope data expected in Lyme disease prevention.
Is Tarsus profitable?
Not yet. Tarsus had a $7.0 million net loss in Q1 2026 and an accumulated deficit of $433.6 million as of March 31, 2026, though losses have narrowed sharply.